AR013079A1 - Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios - Google Patents
Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediariosInfo
- Publication number
- AR013079A1 AR013079A1 ARP980102069A ARP980102069A AR013079A1 AR 013079 A1 AR013079 A1 AR 013079A1 AR P980102069 A ARP980102069 A AR P980102069A AR P980102069 A ARP980102069 A AR P980102069A AR 013079 A1 AR013079 A1 AR 013079A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- onas
- het
- alkenyl
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/22—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/83—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4575897P | 1997-05-06 | 1997-05-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR013079A1 true AR013079A1 (es) | 2000-12-13 |
Family
ID=21939723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980102069A AR013079A1 (es) | 1997-05-06 | 1998-05-04 | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1003846A4 (tr) |
| JP (1) | JP2001525804A (tr) |
| KR (1) | KR20010012256A (tr) |
| CN (1) | CN1255161A (tr) |
| AR (1) | AR013079A1 (tr) |
| AU (1) | AU7562598A (tr) |
| BR (1) | BR9809306A (tr) |
| CA (1) | CA2288868A1 (tr) |
| CO (1) | CO4950618A1 (tr) |
| HU (1) | HUP0002247A3 (tr) |
| IL (1) | IL132088A0 (tr) |
| NO (1) | NO995434D0 (tr) |
| NZ (1) | NZ337889A (tr) |
| PE (1) | PE71599A1 (tr) |
| PL (1) | PL336856A1 (tr) |
| TR (1) | TR199902766T2 (tr) |
| UY (1) | UY25143A1 (tr) |
| WO (1) | WO1998050533A1 (tr) |
| ZA (1) | ZA983762B (tr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO5150165A1 (es) * | 1998-11-13 | 2002-04-29 | Smithkline Beecham Plc | Inhibidores de proteasa: tipo catepsina k |
| DZ3083A1 (fr) * | 1999-02-19 | 2004-06-02 | Smithkline Beecham Corp | Composés nouveaux inhibiteurs de protéases, procédé pour leur préparation et compositions pharmaceutiques les conentant. |
| GB9911417D0 (en) * | 1999-05-18 | 1999-07-14 | Peptide Therapeutics Ltd | Furanone derivatives as inhibitors of cathepsin s |
| WO2001034599A1 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
| US20040024000A1 (en) * | 2000-10-19 | 2004-02-05 | Rajeshwar Singh | Dihydropyrimidine derivatives as cysteine protease inhibitors |
| JP2004513942A (ja) * | 2000-11-17 | 2004-05-13 | メディヴァー ユーケイ リミテッド | システインプロテアーゼインヒビター |
| JP2004520439A (ja) * | 2000-11-17 | 2004-07-08 | メディヴィル・アクチボラグ | システインプロテアーゼインヒビター |
| JP2004522738A (ja) * | 2001-01-17 | 2004-07-29 | アミュラ テラピューティクス リミテッド | クルジパインおよび他のシステインプロテアーゼの阻害剤としての環状２−カルボニルアミノケトン |
| US7132449B2 (en) | 2001-01-17 | 2006-11-07 | Amura Therapeutics Limited | Inhibitors of cruzipain and other cysteine proteases |
| AU2002219397B2 (en) * | 2001-01-17 | 2008-02-14 | Grünenthal GmbH | Inhibitors of cruzipain and other cysteine proteases |
| NZ526912A (en) * | 2001-01-17 | 2005-02-25 | Amura Therapeutics Ltd | Inhibitors of cruzipain and other cysteine proteases |
| WO2003037892A1 (en) * | 2001-10-29 | 2003-05-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as reversible inhibitors of cysteine proteases |
| NZ537853A (en) * | 2002-07-16 | 2007-02-23 | Amura Therapeutics Ltd | Inhibitors of cathepsin K and related cysteine protesases of the CA clan |
| KR100962972B1 (ko) | 2002-07-26 | 2010-06-09 | 주식회사유한양행 | 1-페닐피페리딘-3-온 유도체 및 그의 제조방법 |
| BRPI0413324A (pt) | 2003-08-06 | 2006-10-10 | Senomyx Inc | receptores de paladar hetero-oligoméricos t1r, linhas de células que expressam os ditos receptores, e compostos de paladar |
| AU2016206281B2 (en) * | 2003-08-06 | 2017-11-30 | Senomyx, Inc. | Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof |
| DE602005019971D1 (de) * | 2004-01-08 | 2010-04-29 | Medivir Ab | Inhibitoren von cysteinprotease |
| CA2619706A1 (en) * | 2005-08-17 | 2007-02-22 | Schering Corporation | Novel high affinity quinoline-based kinase ligands |
| GB0614042D0 (en) | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| MX2009012847A (es) * | 2007-06-13 | 2009-12-08 | Bristol Myers Squibb Co | Analogos dipeptidicos como inhibidores de factores de coagulacion. |
| US7893067B2 (en) | 2007-06-27 | 2011-02-22 | Medivir Ab | Cysteine protease inhibitors |
| EP2240491B1 (en) | 2008-01-09 | 2015-07-15 | Amura Therapeutics Limited | TETRAHYDROFURO(2,3-b)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES |
| GB0817424D0 (en) * | 2008-09-24 | 2008-10-29 | Medivir Ab | Protease inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3190431B2 (ja) * | 1991-07-01 | 2001-07-23 | 三菱化学株式会社 | ケトン誘導体 |
| JPH05140063A (ja) * | 1991-11-19 | 1993-06-08 | Suntory Ltd | ジペプチド誘導体及びそれを有効成分とする骨疾患の予防及び治療剤 |
| CA2111930A1 (en) * | 1992-12-25 | 1994-06-26 | Ryoichi Ando | Aminoketone derivatives |
| JP2848232B2 (ja) * | 1993-02-19 | 1999-01-20 | 武田薬品工業株式会社 | アルデヒド誘導体 |
| JP3599287B2 (ja) * | 1993-04-28 | 2004-12-08 | 三菱化学株式会社 | スルホンアミド誘導体 |
| US5403952A (en) * | 1993-10-08 | 1995-04-04 | Merck & Co., Inc. | Substituted cyclic derivatives as novel antidegenerative agents |
| SK88997A3 (en) * | 1995-10-30 | 1998-05-06 | Smithkline Beecham Corp | Method of inhibiting cathepsin k |
| TW448172B (en) * | 1996-03-08 | 2001-08-01 | Pharmacia & Upjohn Co Llc | Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation |
| WO1998004539A1 (fr) * | 1996-07-29 | 1998-02-05 | Mitsubishi Chemical Corporation | Derives heterocycliques oxygenes |
-
1998
- 1998-05-04 AR ARP980102069A patent/AR013079A1/es unknown
- 1998-05-05 PE PE1998000336A patent/PE71599A1/es not_active Application Discontinuation
- 1998-05-05 ZA ZA983762A patent/ZA983762B/xx unknown
- 1998-05-06 CO CO98024945A patent/CO4950618A1/es unknown
- 1998-05-06 CN CN98804791A patent/CN1255161A/zh active Pending
- 1998-05-06 EP EP98923299A patent/EP1003846A4/en not_active Withdrawn
- 1998-05-06 WO PCT/US1998/003200 patent/WO1998050533A1/en not_active Application Discontinuation
- 1998-05-06 KR KR1019997010207A patent/KR20010012256A/ko not_active Application Discontinuation
- 1998-05-06 JP JP54804998A patent/JP2001525804A/ja active Pending
- 1998-05-06 BR BR9809306-1A patent/BR9809306A/pt not_active Application Discontinuation
- 1998-05-06 PL PL98336856A patent/PL336856A1/xx unknown
- 1998-05-06 HU HU0002247A patent/HUP0002247A3/hu unknown
- 1998-05-06 TR TR1999/02766T patent/TR199902766T2/tr unknown
- 1998-05-06 IL IL13208898A patent/IL132088A0/xx unknown
- 1998-05-06 NZ NZ337889A patent/NZ337889A/en unknown
- 1998-05-06 CA CA002288868A patent/CA2288868A1/en not_active Abandoned
- 1998-05-06 AU AU75625/98A patent/AU7562598A/en not_active Abandoned
- 1998-08-17 UY UY25143A patent/UY25143A1/es unknown
-
1999
- 1999-11-05 NO NO995434A patent/NO995434D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO995434L (no) | 1999-11-05 |
| KR20010012256A (ko) | 2001-02-15 |
| TR199902766T2 (tr) | 2000-02-21 |
| CA2288868A1 (en) | 1998-11-12 |
| EP1003846A1 (en) | 2000-05-31 |
| WO1998050533A1 (en) | 1998-11-12 |
| NO995434D0 (no) | 1999-11-05 |
| PL336856A1 (en) | 2000-07-17 |
| UY25143A1 (es) | 1998-11-27 |
| CO4950618A1 (es) | 2000-09-01 |
| JP2001525804A (ja) | 2001-12-11 |
| IL132088A0 (en) | 2001-03-19 |
| AU7562598A (en) | 1998-11-27 |
| CN1255161A (zh) | 2000-05-31 |
| HUP0002247A3 (en) | 2003-01-28 |
| PE71599A1 (es) | 1999-09-15 |
| HUP0002247A2 (hu) | 2001-05-28 |
| BR9809306A (pt) | 2000-07-04 |
| EP1003846A4 (en) | 2002-11-13 |
| NZ337889A (en) | 2001-09-28 |
| ZA983762B (en) | 1998-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR013079A1 (es) | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios | |
| ECSP055701A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos | |
| AR035792A1 (es) | Compuestos de n-(4-quinazolinil)-n-(1h-indazol-5-il) amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y metodo para prepararlo | |
| AR003440A1 (es) | Nuevos derivados de aminoacidos, formulacion farmaceutica que los contiene, uso de dichos derivados para preparar medicamentos y procedimiento para la preparacion de dichos derivados. | |
| ES2161290T3 (es) | Derivados de quinazolina. | |
| BR0215240A (pt) | Derivados de calcona e seu uso no tratamento de doenças | |
| ECSP034732A (es) | Derivado de fenetanolamina para el tratamiento de enfermedades respiratorias | |
| AR032136A1 (es) | Compuestos espiroheterociclicos utiles como inhibidores reversibles de cisteina-proteasas | |
| ECSP941104A (es) | Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| PT97638A (pt) | Processo para a preparacao de compostos peptidicos e de composicoes farmaceuticas que os contem | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| BR0116452A (pt) | Composto, composição farmacêutica, uso de um composto | |
| BRPI0108395B8 (pt) | derivados de pirrolopirimidinona, processos de preparação e uso | |
| EE200100485A (et) | Uudsed ühendid ja kompositsioonid proteaasi inhibiitoritena | |
| UY27755A1 (es) | Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores. | |
| ES2062943B1 (es) | Nuevos derivados de la (2-metil-3-piridil) cianometilpiperazinas. | |
| AR029403A1 (es) | Derivados n-sustituidos de carbamoiloxialquil-azolio,un proceso para su fabricacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento | |
| BR0210122A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo | |
| BR0214243A (pt) | Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida | |
| AR054129A1 (es) | Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7 | |
| AR004961A1 (es) | Modificacion cristalina v del clorhidrato de(r)-(-)-2-{n-[4-(1,1-dioxido-3- oxo-2,3-dihidro-benzisotiazol-2-il)-butil]-aminometil)cromano, unprocedimiento para su preparacion, medicamentos que lo contienen, el uso de dicho clorhidrato para la preparacion de medicamentos, una composicion para el | |
| LV12291A (lv) | Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai | |
| BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
| MX9205123A (es) | Derivados de 5-hidroxi-2-pirimidinilmetileno utiles como agentes anti-inflamatorios. | |
| ES2111352T3 (es) | Uso de diester fosfato para el tratamiento de enfermedades retinianas. |